MusclePharm (MSLPQ) 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	MusclePharm Corp
Entity Central Index Key	1415684
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Trading Symbol	MSLP
Entity Common Stock, Shares Outstanding		13,492,191

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash	$4,784	$1,020
Accounts receivable, net of allowance for doubtful accounts of $187 and $159 as of March 31, 2015 and December 31, 2014	18,959	16,644
Inventory	13,872	21,069
Prepaid giveaways	1,474	1,228
Prepaid stock compensation, current	4,236	4,476
Prepaid sponsorship and endorsement fees	397	238
Prepaid expenses and other current assets	2,044	1,742
Total current assets	45,766	46,417
Property and equipment, net	7,470	7,805
Intangible assets, net	9,195	7,074
Prepaid stock compensation, long-term	5,282	4,952
Other assets	188	108
TOTAL ASSETS	67,901	66,356
Current liabilities:
Accounts payable	28,826	27,761
Accrued liabilities	6,050	7,023
Line of credit	8,000	8,000
Term loan, current portion	1,271
Other debt obligations	46	46
Total current liabilities	44,193	42,830
Term loan, non-current portion	2,625
Other long-term liabilities	114	146
TOTAL LIABILITIES	46,932	42,976
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, par value of $0.001 per share; 100,000,000 shares authorized as of March 31, 2015 and December 31, 2014; 14,367,812 and 13,996,007 shares issued as of March 31, 2015 and December 31, 2014; 13,492,191 and 13,120,386 shares outstanding as of March 31, 2015 and December 31, 2014	14	14
Additional paid-in capital	134,278	129,130
Treasury stock, at cost; 875,621 shares as of March 31, 2015 and December 31, 2014	-10,039	-10,039
Accumulated other comprehensive loss	-146	-66
Accumulated deficit	-103,138	-95,659
TOTAL STOCKHOLDERS’ EQUITY	20,969	23,380
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$67,901	$66,356

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]
Accounts receivable, net of allowance for doubtful accounts	$187	$159
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	14,367,812	13,996,007
Common Stock, shares outstanding	13,492,191	13,120,386
Treasury Stock, shares	875,621	875,621

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenue, net	$41,322	$50,209
Cost of revenue	26,938	32,336
Gross profit	14,384	17,873
Operating expenses:
Advertising and promotion	7,225	6,328
Salaries and benefits	7,061	5,367
Selling, general and administrative	4,962	1,872
Research and development	965	1,097
Professional fees	1,455	785
Total operating expenses	21,668	15,449
(Loss) income from operations	-7,284	2,424
Other (expense) income, net	-183	344
(Loss) income before provision for income taxes	-7,467	2,768
Provision for income taxes	12	32
Net (loss) income	($7,479)	$2,736
Net (loss) income per share, basic	($0.56)	$0.27
Net (loss) income per share, diluted	($0.56)	$0.23
Weighted average shares used to compute net (loss) income per share, basic	13,333,868	10,307,350
Weighted average shares used to compute net (loss) income per share, diluted	13,333,868	11,951,923

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	($7,479)	$2,736
Other comprehensive (loss) income:
Change in foreign currency translation adjustment	-80	-4
Comprehensive (loss) income	($7,559)	$2,732

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Unaudited) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Balance at Dec. 31, 2014	$23,380	$14	$129,130	($10,039)	($66)	($95,659)
Balance (in shares) at Dec. 31, 2014	13,120,386	13,120,386
Issuance of common stock warrants to third parties for services	33		33
Stock-based compensation related to issuance of restricted stock awards to employees, executives and directors	2,523		2,523
Stock-based compensation related to issuance of restricted stock awards to employees, executives and directors (in shares)	51,805	51,805
Stock issued in conjunction with energy drink agreements	1,198		1,198
Stock issued in conjunction with energy drink agreement (in shares)	150,000	150,000
Stock issued in conjunction with MusclePharm Apparel acquisition	1,394		1,394
Stock issued in conjunction with MusclePharm Apparel acquisition (in shares)	170,000	170,000
Net (loss) income	-7,479					-7,479
Change in foreign currency translation adjustment	-80				-80
Balance at Mar. 31, 2015	$20,969	$14	$134,278	($10,039)	($146)	($103,138)
Balance (in shares) at Mar. 31, 2015	13,492,191	13,492,191

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	($7,479)	$2,736
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation of property and equipment	382	314
Amortization of intangible assets	225	285
Provision for doubtful accounts	30	76
Amortization of prepaid stock compensation	1,109	795
Amortization of prepaid sponsorship and endorsement fees	1,431	1,658
Accretion of discount on marketable securities		-15
Amortization of debt issuance costs	9
Stock-based compensation	2,523	2,376
Issuance of common stock warrants to third parties for services	33
Gain on settlement of accounts payable		-5
Loss (gain) on disposal of property and equipment	7	-2
Change in fair value of derivative liabilities		-484
Unrealized loss on derivative assets		119
Unrealized loss on marketable securities		60
Changes in operating assets and liabilities:
Accounts receivable	-2,345	-5,163
Inventory	7,197	-41
Prepaid giveaways	-247	-113
Prepaid sponsorship and endorsement fees	-1,590	-968
Prepaid expenses and other current assets	-272	85
Other assets	-79	3
Accounts payable	719	-2,874
Accrued liabilities	-971	390
Net cash provided by (used in) operating activities	682	-768
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	-257	-1,304
Change in restricted cash balance		-1
Proceeds from disposal of property and equipment	447	2
Purchase of MusclePharm Apparel Rights	-850
Net cash used in investing activities	-660	-1,303
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from line of credit	4,001
Payments on line of credit	-4,001
Repayments of term loan	-103	-3
Proceeds from issuance of term loan	4,000
Issuance costs of term loan	-40
Repayment of capital lease obligations	-35	-18
Net cash provided by (used in) financing activities	3,822	-21
Effect of exchange rate changes on cash	-80	-4
NET INCREASE (DECREASE) IN CASH	3,764	-2,096
CASH — BEGINNING OF PERIOD	1,020	5,412
CASH — END OF PERIOD	4,784	3,316
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	124	36
Cash paid for taxes	40	83
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Stock issued in conjunction with energy drink agreements	1,198
Stock issued in conjunction with MusclePharm Apparel acquisition	1,394	9,840
Common stock issued for board member compensation		115
Purchase of property and equipment included in accounts payable and accrued liabilities	244
Purchase of trademark registration included in accounts payable and accrued liabilities	$102

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	Note 1: Description of Business and Basis of Presentation
	Description of Business
	MusclePharm Corporation, or the Company, was incorporated in Nevada in 2006. The Company is a scientifically driven, performance lifestyle company that develops, manufactures, markets and distributes branded nutritional supplements. The Company is headquartered in Denver, Colorado and has the following wholly-owned operating subsidiaries: MusclePharm Canada Enterprises Corp (“MusclePharm Canada”), BioZone Laboratories, Inc. (“BioZone Labs”) and MusclePharm Ireland (“MusclePharm Ireland”).
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
	Reclassifications
	Certain prior period amounts have been reclassified to conform to the current period presentation.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2: Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries. Acquisitions are included in the consolidated financial statements from the date of the acquisition. All significant intercompany balances and transactions have been eliminated in consolidation.
	Unaudited Interim Financial Information
	The accompanying consolidated balance sheet as of March 31, 2015, and the consolidated statements of operations, comprehensive (loss) income, stockholder’s equity and cash flows for the three months ended March 31, 2014 and 2015 are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). In our opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of March 31, 2015, our results of operations for the three months ended March 31, 2014 and 2015, and our cash flows for the three months ended March 31, 2014 and 2015. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015.
	These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 16, 2015.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts and sales reserves, valuations of equity securities and intangible assets, fair value of derivatives and fair values of warrants and options, among others. Actual results could differ from those estimates.
	Recent Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board ("FASB") issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which provides guidance on simplifying the presentation of debt issuance costs, requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This standard requires retrospective adoption and will be effective for the Company beginning in its first quarter of 2016. The Company does not expect this standard to have a material impact on its financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2014-15.
	In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation – Stock Compensation”, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material effect on the Company’s consolidated financial statements or disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers" (“ASU 2014-09”), which provides guidance for revenue recognition. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets and supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition- Construction-Type and Production-Type Contracts.” ASU 2014-09’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company beginning January 1, 2017 and, at that time, the Company may adopt the new standard under the full retrospective approach or the modified retrospective approach. Early adoption is not permitted. The Company has not yet selected a transition method nor has determined the effect of ASU 2014-09 on its ongoing financial reporting.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3: Fair Value of Financial Instruments
	The Company’s financial instruments consisted primarily of accounts receivable, accounts payable, accrued liabilities and debt. The Company’s debt approximates fair value based upon current borrowing rates available to the Company for debt with similar maturities.

Acquisition

Acquisition	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Acquisition	Note 4: Acquisition
	Capstone Nutrition Agreement
	Effective March 2, 2015, the Company and Capstone Nutrition (“Capstone”) executed an amendment (the “Amendment”) to the Manufacturing Agreement dated November 27, 2013. Pursuant to the Amendment, Capstone shall be the Company’s nonexclusive manufacturer of dietary supplements and food products sold or intended to be sold by the Company (the “Products”). The Company shall purchase and take delivery from Capstone a minimum of $90.0 million of Products per full contract year. The Amendment includes amended pricing for Products and payment terms. The initial term ends January 1, 2022 and will continue thereafter for three successive twenty-four month terms, unless Capstone notifies the Company of nonrenewal at least ninety days prior to the end of the then current term.
	Payment and Rebates. The Company and Capstone agreed on certain payment terms and rebate programs.
	Contribution toward Capstone Facility Build-Out. The Company agreed to pay to Capstone a non-refundable sum of $2.5 million to be used by Capstone solely in connection with the expansion of its facility necessary to fulfill anticipated Company requirements under the Manufacturing Agreement and Amendment. Payment of the $2.5 million is due in three (3) equal installments 30, 60 and 90 days from the effective date.
	Capstone and the Company entered into a referral agreement (the “Referral Agreement”) whereby the Company will refer customers to Capstone for the purchase of products, and Capstone will pay the Company a referral fee. The term of the Referral Agreement will continue as long as the Manufacturing Agreement between the Company and Capstone is in effect.
	The Company and Capstone entered into a Class B Common Stock Warrant Purchase Agreement (“Warrant Agreement”) whereby the Company may purchase 19.9% of Capstone’s parent company, INI Parent, Inc. (“INI”), on a fully-diluted basis. Pursuant to the Warrant Agreement, INI issued to the Company a warrant (the “Warrant”) to purchase shares of INI’s Class B common stock, par value $0.001 per share at an exercise price of $0.01 per share (the “Warrant Shares”).
	The Company has the right to exercise the Warrant under certain circumstances: (i) the Warrant Agreement may only be exercised at the earlier of (A) immediately prior to, and in connection with the consummation of a sale of INI or (B) within five business days of the expiration of the initial terms of the Manufacturing Agreement; (ii) the Company has been and continues to be as of the date of the sale of INI in compliance with the terms of the Manufacturing Agreement; and (iii) the Company complies with the provisions of the Warrant Agreement, including its exercise conditions. The Warrant Agreement and Warrant Shares are not transferrable without the prior written consent of INI’s Board of Directors.
	In lieu of exercising the Warrant Agreement, the Company may elect to sell or terminate the Warrant Agreement provided that the Company makes such election by delivering written notice to INI pursuant to the terms and conditions of the Warrant Agreement.
	In connection with the Warrant Agreement, the Company and INI entered into an option agreement (the “Option Agreement”). Subject to additional provisions and conditions set forth in the Option Agreement, at any time on or prior to June 30, 2016, the Company shall have the right to purchase for cash all of the remaining outstanding shares of INI’s common stock not already owned by the Company after giving effect to the exercise of the Warrant on a fully-diluted basis, based on an aggregate enterprise value, equal to $200 million. Such purchase is intended to be consummated pursuant to a definitive merger agreement whereby INI would merge with a subsidiary of the Company and survive the merger as a wholly-owned subsidiary to the Company. In April 2015, the Company made its first payment to Capstone pursuant to the Manufacturing Agreement and Amendment. The Company is in the process of completing the valuation of the various contract elements which are expected to be included in the results for the six months ended June 30, 2015.

Balance_Sheet_Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Disclosures	Note 5: Balance Sheet Components
	Inventory
	Inventory consisted of the following as of March 31, 2015 and December 31, 2014 (in thousands):
			March 31, 2015			December 31, 2014
	Raw materials		$	1,884		$	1,169
	Work-in-process			305			101
	Finished goods			11,683			19,799
	Inventory		$	13,872		$	21,069
	The Company writes down inventory for obsolete and slow moving inventory based on the age of the product as determined by the expiration date. Products within one year of their expiration dates are considered for write-off purposes. Historically, we have had minimal returns with established customers, and any damaged packaging is sent back to the manufacturer for replacement. We incurred insignificant inventory write-off during the three months ended March 31, 2015 and 2014.
	Property and Equipment
	Property and equipment consisted of the following as of March 31, 2015 and December 31, 2014 (in thousands):
			March 31, 2015			December 31, 2014
	Furniture and fixtures		$	3,954		$	4,041
	Leasehold improvements			2,932			2,298
	Manufacturing and lab equipment			1,536			1,388
	Vehicles			470			470
	Displays			486			488
	Website			399			241
	Office equipment and computers			141		—
	Construction in process			561			1,511
	Property and equipment, gross			10,479			10,437
	Less: accumulated depreciation and amortization			(3,009	)		(2,632	)
	Property and equipment, net		$	7,470		$	7,805
	Depreciation and amortization expense related to property and equipment was $382,000 and $314,000 for the three months ended March 31, 2015 and 2014, which is included in the selling, general, and administrative in the consolidated statements of operations.
	Intangible Assets
	Intangible assets consist of the following (in thousands) and includes the acquisition of MusclePharm’s apparel rights from Worldwide Apparel disclosed further in footnote 10:
			As of March 31, 2015
			Gross Value			Accumulated Amortization			Net		Weighted-
									Carrying		Average
									Value		Useful Lives
											(years)
	Amortized Intangible Assets
	Customer relationships		$	3,130		$	(261	)	$	2,869		15
	Non-compete agreements			69			(43	)		26		0.8
	Patents			2,211			(354	)		1,857		7.8
	Trademarks			692			(117	)		575		6.3
	Brand			4,020			(194	)		3,826		9.2
	Domain name			68			(26	)		42		5
	Total intangible assets		$	10,190		$	(995	)	$	9,195
			As of December 31, 2014
			Gross Value			Accumulated Amortization			Net		Weighted-
									Carrying		Average
									Value		Useful Lives
											(years)
	Amortized Intangible Assets
	Customer relationships		$	3,130		$	(209	)	$	2,921		15
	Non-compete agreements			69			(35	)		34		2
	Patents			2,211			(293	)		1,918		7.8
	Trademarks			518			(20	)		498		4.5
	Brand			1,776			(118	)		1,658		15
	Domain name			68			(23	)		45		5
	Total intangible assets		$	7,772		$	(698	)	$	7,074
	Intangible amortization expense for the three months ended March 31, 2015 and 2014 was $225,000 and $285,000, which is recorded in the selling, general, and administrative in the consolidated statements of operations.
	As of March 31, 2015, the estimated future amortization expense of intangible assets is as follows (in thousands):
	Year Ending December 31,
	The remainder of 2015			$	816
		2016			1,054
		2017			1,042
		2018			1,031
		2019			1,027
		2020			983
	Thereafter				3,242
	Total amortization expense			$	9,195

Other_Income_Expensenet

Other Income (Expense),net	3 Months Ended
	Mar. 31, 2015
Other Income Expense Net [Abstract]
Other Income (Expense),net	Note 6: Other Income (Expense), net
	During the three months ended March 31, 2015 and 2014, other income (expense), net consists of the following (in thousands):
		Three Months Ended March 31,
		2015			2014
	Other (expense) income, net:
	Interest income	$	—		$	223
	Interest expense		(125	)		(39	)
	Change in fair value of derivative liabilities		—			484
	Gain on settlement of accounts payable		—			5
	Loss on marketable securities		—			(386	)
	Foreign currency transaction loss		(64	)		(30	)
	Other		6			87
	Total other (expense) income, net	$	(183	)	$	344

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	Note 7: Debt
	In September 2014, the Company entered into a line of credit facility with a banking institution for up to $8.0 million of borrowings. The line of credit matures in September 2017 and accrues interest at the prime rate plus 2%, currently 5.25%. The line of credit is secured by the Company’s inventory, accounts receivable, intangible assets and equipment. As of March 31, 2015 and December 31, 2014, the Company had drawn down all $8.0 million under the line of credit. The Company would not have been in compliance with certain financial covenants, including requiring the balance to be at or below $3 million for a minimum of 14 non-consecutive days per quarter, under this facility as of March 31, 2015 and December 31, 2014, and received a written waiver from the bank until May 31, 2015.
	In February 2015, the Company entered into a term loan agreement with the same banking institution for a principal amount of $4.0 million. The term loan carries a fixed interest rate of 5.25% per annum, is repayable in 36 equal monthly installments of principal and interest, and matures in February 2018. Outstanding borrowings are subject to prepayment penalties of 1.0% of the prepayment amount. The Company also paid debt issuance cost of $40,000 which was recorded in prepaid expenses in the consolidated balance sheets.
	Borrowings on the term loan are secured by the Company’s inventory, accounts receivable and other receivables, general intangible properties, and 860,900 shares of common stock held in treasury. The Company is also required to comply with certain negative covenants under the term loan, including restrictions on indebtedness, investments, asset dispositions, mergers or consolidations and other corporate activities. The Company would not have been in compliance with certain financial covenants and received a written waiver from the bank until May 31, 2015.
	In December 2014, the Company entered into a fleet lease program providing for the Company approximately $1.8 million in credit to lease up to 50 vehicles.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8: Commitments and Contingencies
	Operating Leases and Capital Leases
	The Company leases office and warehouse facilities under operating leases which expire at various dates through 2029. For lease agreements that contain escalating rent provisions, lease expense is recorded on a straight-line basis over the lease term. Rent expense for the three months ended March 31, 2015 and 2014 amounted to $383,000 and $297,000, respectively.
	The Company also leases manufacturing and warehouse equipment under capital leases which expire at various dates through 2017. As of March 31, 2015 and December 31, 2014, the Company had an outstanding balance on capital leases of $229,000 and $265,000 respectively, which were included as a component of accrued liabilities and other long-term liabilities in the consolidated balance sheets.
	Contingencies
	In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. As of March 31, 2015 and December 31, 2014, the Company was not involved in any material legal proceedings, except for the SEC investigation discussed below and routine litigation experienced in the ordinary course of its business.
	SEC Investigation
	In July 2013, the Company received a formal order of investigation (the “Investigation”) from the Denver Regional Office of the SEC which is actively investigating various areas of potential violation of the federal securities laws involving the Company and its management. The SEC has issued subpoenas for documents and testimony and has deposed numerous witnesses in connection with the Investigation. As a result of a review undertaken by the Company’s personnel in conjunction with the Audit Committee of the Board of Directors during 2014, the Company amended certain prior reports to revise various disclosures concerning executive compensation and disclosure of perquisites, among other things, and filed amendments to the annual reports on Form 10-K for the fiscal years ended December 31, 2013, 2012 and 2011. The Investigation remains ongoing. The Investigation could lead to the SEC seeking fines, penalties, injunctive relief and the adoption of corrective plans to establish reporting and other practices affecting the Company. The Company has reached an agreement in principle with the staff of the Enforcement Division of the SEC Denver Regional Office to resolve the investigation by the SEC, however, such agreement must be approved by the SEC Commissioners. Neither the nature of the relief, the amount of any monetary relief, nor the nature of the corrective actions, whether voluntary or imposed as a result of court proceedings that could be sought by the SEC, can be predicted. The result of any of the foregoing could have a material adverse effect on the Company or its management.
	Product Liability
	Additionally, as a manufacturer of nutritional supplements and other consumer products that are ingested by consumers, the Company may be subject to various product liability claims. The Company currently maintains product liability insurance with a deductible/retention of $10,000 per claim with an aggregate cap on retained loss of $20.0 million. As of March 31, 2015 and December 31, 2014, the Company had not recorded an accrual for product liability claims. There can be no assurance that insurance coverage will be available for product liability claims or other claims experienced in the ordinary course of the Company’s business.
	Insurance Carrier Lawsuit
	In an effort to recover SEC legal defense costs, the Company engaged with outside counsel to review, evaluate and advise on the current Director and Officer policy and corresponding coverages. On February 12, 2015, the Company filed a complaint and jury demand in the District Court, City and County of Denver, Colorado against Liberty Insurance Underwriters, Inc. This action arises from the wrongful and unreasonable denial of coverage by Liberty for the cost and expenses that the Company has incurred and will continue to incur in connection with the SEC investigation under the Company’s Directors and Officers Insurance policies.
	Sponsorship and Endorsement Contract Liabilities
	The Company has various non-cancelable endorsement and sponsorship agreements with terms expiring through 2018. The total value of future contractual payments as of March 31, 2015 and December 31, 2014 was $50.0 million and $52.8 million. The total future contractual payments as of March 31, 2015 are as follows (in thousands):
		Year Ending December 31,
		Remainder		2016		2017		2018		2019		Thereafter		Total
		of 2015
	Outstanding Payments
	Endorsement	$	5,280	$	8,203	$	9,105	$	6,000	$	4,167	$	11,667	$	44,422
	Sponsorship		3,898		1,488		100		100		—		—		5,586
	Total future payments	$	9,178	$	9,691	$	9,205	$	6,100	$	4,167	$	11,667	$	50,008

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
Stockholders’ Equity	Note 9: Stockholders’ Equity
	Common Stock
	For the three months ended March 31, 2015, the Company issued common stock including restricted stock awards, as follows:
	Transaction Type	Quantity		Valuation		Range of
		(#)		($ in thousands)		Value per
						Share
	Stock issued to employees, executives and directors		51,805	$	2,523	$	3.48 – 8.60
	Stock issued in conjunction with energy drink agreement		150,000		1,198		7.99
	Stock issued in conjunction with MusclePharm apparel rights acquisition		170,000		1,394		8.2
	Total		371,805	$	5,115	$	3.48 – 8.60
	For the three months ended March 31, 2014, the Company issued common stock including restricted stock awards, as follows:
	Transaction Type	Quantity		Valuation		Range of
		(#)		($ in thousands)		Value per
						Share ($)
	Stock issued to employees, executives and directors		60,422	$	2,491	$	3.48 – 8.70
	BioZone acquisition		1,200,000		9,840		8.2
	Total		1,260,422	$	12,331	$	3.48 – 8.70
	The fair value of all stock issuances above is based upon either the quoted closing trading price on the date of issuance or the value of derivative instrument at the date of conversion.
	Treasury Stock
	For the three months ended March 31, 2015 and 2014, the Company did not repurchase any shares of its common stock and held 875,621 shares in treasury as of March 31, 2015.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Note 10: Stock-Based Compensation
	The Company’s stock-based compensation for the three months ended March 31, 2015 and 2014 consist primarily of restricted stock awards. The activity of restricted stock awards granted to employees and board members was as follows:
		Unvested Restricted
		Stock Awards
		Number of			Weighted-
		Shares			Average Grant
					Date Fair
					Value
	Unvested balance – December 31, 2014		2,631,987		$	11.67
	Granted		8,668			8.6
	Vested		(366,889	)		9.87
	Unvested balance – March 31, 2015		2,273,766		$	12.01
	The total fair value of restricted stock awards granted to employees and board members for the three months ended March 31, 2015 and 2014 was $75,000 and $320,000. As of March 31, 2015 and December 31, 2014, the total unrecognized expense for unvested restricted stock awards, net of expected forfeitures, was $18.2 million and $20.7 million, which are expected to be amortized over a weighted-average period of 3.1 and 2.6 years.
	Restricted Stock Awards Related to Energy Drink Agreement
	In January 2015, the Company entered into an energy drink agreement with Langer Juice and Creative Labs. In connection with the agreement, the Company issued a total of 150,000 shares of its restricted common stock which vest monthly over a period of three years. The restricted stock awards have a grant date fair value of approximately $1.2 million, which are included as a component of prepaid stock compensation and additional paid-in capital in the consolidated balance sheets. The prepaid stock compensation is being amortized over the performance period of three years.
	Agreements with Worldwide Apparel, LLC – Muscle Pharm Apparel Rights
	In February 2015, the Company entered into an agreement with Worldwide Apparel, LLC (“Worldwide”) to terminate Worldwide’s right to use MusclePharm’s brand images in apparel effective March 28, 2014. The brand rights were originally licensed in May 2011, and amended in March 2014 prior to the termination. The consideration related to the acquisition of the MusclePharm Apparel from Worldwide consists of a cash consideration of $850,000 and 170,000 shares of MusclePharm common stock with an aggregated fair value of $1.4 million on issuance date. For the total 170,000 shares issued, 42,500 shares are held in escrow and will be released to Worldwide on May 22, 2015 if no claim is made. The total cost of the MusclePharm apparel acquisition of $2.2 million was included as brand in intangible assets, net in the accompanying balance sheet, and is subject to amortization over a period of seven years.

Net_Income_Loss_Per_Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Note 11: Net Income (Loss) per Share
	The following table sets forth the computation of the Company’s basic and diluted net (loss) income per share for the periods presented (in thousands, except share and per share data):
		Three Months Ended March 31,
		2015			2014
	Net (loss) income	$	(7,479	)	$	2,736
	Weighted-average common shares used in computing net (loss) income per share, basic		13,333,868			10,307,350
	Effect of dilutive securities		—			1,644,573
	Weighted-average common shares used in computing net (loss) income per share, diluted		13,333,868			11,951,923
	Net (loss) income per share, basic	$	(0.56	)	$	0.27
	Net (loss) income per share, diluted	$	(0.56	)	$	0.23
	The following securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:
		Three Months Ended March 31,
		2015			2014
	Stock options (exercise price - $425/share)		472			472
	Warrants (exercise price - $4 - $1,275/share)		—			263,089
	Unvested restricted stock		2,273,766			1,381,573
	Total common stock equivalents		2,274,238			1,645,134

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 12: Income Taxes
	The Company recorded an income tax provision of $12,000 and $32,000 for the three months ended March 31, 2015 and 2014 respectively, related to foreign income taxes and state minimum taxes.
	Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due. Deferred taxes relate to differences between the basis of assets and liabilities for financial and income tax reporting which will be either taxable or deductible when the assets or liabilities are recovered or settled. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of March 31, 2015.

Geographical_Information

Geographical Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Geographical Information	Note 13: Geographical Information
	Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands):
		Three Months Ended March 31,
		2015		2014
	Revenue, net:
	United States	$	31,588	$	33,000
	International		9,734		17,209
	Total revenue, net	$	41,322	$	50,209

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 14: Subsequent Events
	Amendment to Bylaws
	On May 8, 2015, the Company’s Board of Directors approved an amendment (the “Amendment”) to the Company’s Amended and Restated Bylaws. A copy of such Amendment is attached hereto as Exhibit 3.1. Pursuant to the Amendment, the Company Bylaws were amended, effective immediately, as follows:
	-	Art. II, Sec. 3, which relates to Special Meetings, was amended and restated to require that stockholders of the Company requesting a special meeting provide, in their request to the Company, certain specified information and set forth other requirements regarding delivery of such request.
	-	Art. II, Sec. 6, which relates to stockholder consents in lieu of stockholder meetings, was amended and restated to require that stockholders intending to act by written consent request a record date from the Company for such action, which request must include certain specified information and set forth other requirements regarding the delivery of written consents.
	-	Art. II, Sec. 9, which relates to advance notice of stockholder proposals and stockholder nominations, was revised to require certain stockholder disclosure requirements.
	-	Art. III, Sec. 2, which relates to Board vacancies, was amended and restated to clarify that only the Board can fill vacancies of the Board.
	-	Art. III, Sec. 11, which relates to the removal of directors, was amended and restated to clarify that directors may be removed by a two-thirds (as opposed to majority) vote of the shareholders, as contemplated by NRS 78.335.
	-	Article VII, Sec. 5, which relates to Forum Selection, was added to the bylaws to provide that that any person acquiring equity in the Company shall be deemed to have notice of and consented to such Article VII. Section 5.
	Corporate Governance Guidelines
	On May 8, 2015, the Company’s Board of Directors adopted updated Corporate Governance Guidelines (“Corporate Guidelines”) effective immediately including reiterating its commitment to review the separation of the responsibilities of the Chairman and Chief Executive Officer.  Such updated Corporate Governance Guidelines are attached hereto as Exhibit 99.2.
	In addition, the Corporate Guidelines identify the position of Lead Independent Director. The Lead Independent Director's responsibilities shall include, but are not limited to: (i) serve as a liaison between the Chairman of the Board and the independent directors; (ii) chair such Board meetings at meetings at which the Chairman is not present; (iii) chairing executive sessions of the independent directors; and (iv) performing such other duties as are assigned from time to time by the Board.
	Communications Policy
	On May 5, 2015 the Company adopted and on May 6, 2015, the Company disseminated to all employees a Corporate Communications Policy (the “Communications Policy”) effective immediately and covering its officers, directors, employees and consultants, in order to better ensure compliance with Corporate Guidelines, ensure the confidentiality of proprietary and/or non-public Company information, and to provide guidance on how to address any issues that may arise from communications whether internally or from outside of the Company. The Communications Policy is attached hereto as Exhibit 99.3.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries. Acquisitions are included in the consolidated financial statements from the date of the acquisition. All significant intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Financial Information	Unaudited Interim Financial Information
	The accompanying consolidated balance sheet as of March 31, 2015, and the consolidated statements of operations, comprehensive (loss) income, stockholder’s equity and cash flows for the three months ended March 31, 2014 and 2015 are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). In our opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of March 31, 2015, our results of operations for the three months ended March 31, 2014 and 2015, and our cash flows for the three months ended March 31, 2014 and 2015. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015.
	These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 16, 2015.
Use of Estimates	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts and sales reserves, valuations of equity securities and intangible assets, fair value of derivatives and fair values of warrants and options, among others. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board ("FASB") issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which provides guidance on simplifying the presentation of debt issuance costs, requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This standard requires retrospective adoption and will be effective for the Company beginning in its first quarter of 2016. The Company does not expect this standard to have a material impact on its financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2014-15.
	In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation – Stock Compensation”, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material effect on the Company’s consolidated financial statements or disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers" (“ASU 2014-09”), which provides guidance for revenue recognition. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets and supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition- Construction-Type and Production-Type Contracts.” ASU 2014-09’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company beginning January 1, 2017 and, at that time, the Company may adopt the new standard under the full retrospective approach or the modified retrospective approach. Early adoption is not permitted. The Company has not yet selected a transition method nor has determined the effect of ASU 2014-09 on its ongoing financial reporting.

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Schedule of Inventory	Inventory consisted of the following as of March 31, 2015 and December 31, 2014 (in thousands):
			March 31, 2015			December 31, 2014
	Raw materials		$	1,884		$	1,169
	Work-in-process			305			101
	Finished goods			11,683			19,799
	Inventory		$	13,872		$	21,069
Schedule of Property, Plant and Equipment	Property and equipment consisted of the following as of March 31, 2015 and December 31, 2014 (in thousands):
			March 31, 2015			December 31, 2014
	Furniture and fixtures		$	3,954		$	4,041
	Leasehold improvements			2,932			2,298
	Manufacturing and lab equipment			1,536			1,388
	Vehicles			470			470
	Displays			486			488
	Website			399			241
	Office equipment and computers			141		—
	Construction in process			561			1,511
	Property and equipment, gross			10,479			10,437
	Less: accumulated depreciation and amortization			(3,009	)		(2,632	)
	Property and equipment, net		$	7,470		$	7,805
Schedule of Intangible Assets	Intangible assets consist of the following (in thousands) and includes the acquisition of MusclePharm’s apparel rights from Worldwide Apparel disclosed further in footnote 10:
			As of March 31, 2015
			Gross Value			Accumulated Amortization			Net		Weighted-
									Carrying		Average
									Value		Useful Lives
											(years)
	Amortized Intangible Assets
	Customer relationships		$	3,130		$	(261	)	$	2,869		15
	Non-compete agreements			69			(43	)		26		0.8
	Patents			2,211			(354	)		1,857		7.8
	Trademarks			692			(117	)		575		6.3
	Brand			4,020			(194	)		3,826		9.2
	Domain name			68			(26	)		42		5
	Total intangible assets		$	10,190		$	(995	)	$	9,195
			As of December 31, 2014
			Gross Value			Accumulated Amortization			Net		Weighted-
									Carrying		Average
									Value		Useful Lives
											(years)
	Amortized Intangible Assets
	Customer relationships		$	3,130		$	(209	)	$	2,921		15
	Non-compete agreements			69			(35	)		34		2
	Patents			2,211			(293	)		1,918		7.8
	Trademarks			518			(20	)		498		4.5
	Brand			1,776			(118	)		1,658		15
	Domain name			68			(23	)		45		5
	Total intangible assets		$	7,772		$	(698	)	$	7,074
Schedule of Estimated Future Amortization Expense of Intangible Assets	As of March 31, 2015, the estimated future amortization expense of intangible assets is as follows (in thousands):
	Year Ending December 31,
	The remainder of 2015			$	816
		2016			1,054
		2017			1,042
		2018			1,031
		2019			1,027
		2020			983
	Thereafter				3,242
	Total amortization expense			$	9,195

Other_Income_ExpenseNet_Tables

Other Income (Expense),Net (Tables)	3 Months Ended
	Mar. 31, 2015
Other Income Expense Net [Abstract]
Other Income (Expense),Net	During the three months ended March 31, 2015 and 2014, other income (expense), net consists of the following (in thousands):
		Three Months Ended March 31,
		2015			2014
	Other (expense) income, net:
	Interest income	$	—		$	223
	Interest expense		(125	)		(39	)
	Change in fair value of derivative liabilities		—			484
	Gain on settlement of accounts payable		—			5
	Loss on marketable securities		—			(386	)
	Foreign currency transaction loss		(64	)		(30	)
	Other		6			87
	Total other (expense) income, net	$	(183	)	$	344

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Contractual Obligation, Fiscal Year Maturity Schedule	The total future contractual payments as of March 31, 2015 are as follows (in thousands):
		Year Ending December 31,
		Remainder		2016		2017		2018		2019		Thereafter		Total
		of 2015
	Outstanding Payments
	Endorsement	$	5,280	$	8,203	$	9,105	$	6,000	$	4,167	$	11,667	$	44,422
	Sponsorship		3,898		1,488		100		100		—		—		5,586
	Total future payments	$	9,178	$	9,691	$	9,205	$	6,100	$	4,167	$	11,667	$	50,008

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
Schedule of Stockholders Equity	For the three months ended March 31, 2015, the Company issued common stock including restricted stock awards, as follows:
	Transaction Type	Quantity		Valuation		Range of
		(#)		($ in thousands)		Value per
						Share
	Stock issued to employees, executives and directors		51,805	$	2,523	$	3.48 – 8.60
	Stock issued in conjunction with energy drink agreement		150,000		1,198		7.99
	Stock issued in conjunction with MusclePharm apparel rights acquisition		170,000		1,394		8.2
	Total		371,805	$	5,115	$	3.48 – 8.60
	For the three months ended March 31, 2014, the Company issued common stock including restricted stock awards, as follows:
	Transaction Type	Quantity		Valuation		Range of
		(#)		($ in thousands)		Value per
						Share ($)
	Stock issued to employees, executives and directors		60,422	$	2,491	$	3.48 – 8.70
	BioZone acquisition		1,200,000		9,840		8.2
	Total		1,260,422	$	12,331	$	3.48 – 8.70

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Restricted Stock Units Activity	The activity of restricted stock awards granted to employees and board members was as follows:
		Unvested Restricted
		Stock Awards
		Number of			Weighted-
		Shares			Average Grant
					Date Fair
					Value
	Unvested balance – December 31, 2014		2,631,987		$	11.67
	Granted		8,668			8.6
	Vested		(366,889	)		9.87
	Unvested balance – March 31, 2015		2,273,766		$	12.01

Net_Income_Loss_Per_Share_Tabl

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net (Loss) Income Per Share	The following table sets forth the computation of the Company’s basic and diluted net (loss) income per share for the periods presented (in thousands, except share and per share data):
		Three Months Ended March 31,
		2015			2014
	Net (loss) income	$	(7,479	)	$	2,736
	Weighted-average common shares used in computing net (loss) income per share, basic		13,333,868			10,307,350
	Effect of dilutive securities		—			1,644,573
	Weighted-average common shares used in computing net (loss) income per share, diluted		13,333,868			11,951,923
	Net (loss) income per share, basic	$	(0.56	)	$	0.27
	Net (loss) income per share, diluted	$	(0.56	)	$	0.23
Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The following securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:
		Three Months Ended March 31,
		2015			2014
	Stock options (exercise price - $425/share)		472			472
	Warrants (exercise price - $4 - $1,275/share)		—			263,089
	Unvested restricted stock		2,273,766			1,381,573
	Total common stock equivalents		2,274,238			1,645,134

Geographical_Information_Table

Geographical Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Revenue, Net by Geographic Area	Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands):
		Three Months Ended March 31,
		2015		2014
	Revenue, net:
	United States	$	31,588	$	33,000
	International		9,734		17,209
	Total revenue, net	$	41,322	$	50,209

Acquisition_Additional_Informa

Acquisition - Additional Information (Details) (USD $)	0 Months Ended	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 02, 2015	Mar. 31, 2015	Feb. 28, 2015	Dec. 31, 2014
		Installments	Installments
Business Acquisition [Line Items]
Number of installments			36
common stock, par value		0.001		$0.00
Capstone
Business Acquisition [Line Items]
Long-term purchase commitment, amount	$90
Contribution toward Capstone Facility Build-	2.5
Number of installments		3
Expansion facility frequency of commitment fee payment		Payment of the $2.5 million is due in three (3) equal installments 30, 60 and 90 days from the effective date.
I N I
Business Acquisition [Line Items]
Percentage ownership interest agreed to purchase	19.90%
Investment Warrants, Exercise Price	$0.01
Aggregate enterprise value	$200
I N I | Common Class B
Business Acquisition [Line Items]
common stock, par value	$0.00

Balance_Sheet_Components_Sched

Balance Sheet Components - Schedule of Inventory (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Net [Abstract]
Raw materials	$1,884	$1,169
Work-in-process	305	101
Finished goods	11,683	19,799
Inventory	$13,872	$21,069

Balance_Sheet_Components_Sched1

Balance Sheet Components - Schedule of Property, Plant and Equipment (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property Plant And Equipment [Line Items]
Property and equipment, gross	$10,479	$10,437
Less: accumulated depreciation and amortization	-3,009	-2,632
Property and equipment, net	7,470	7,805
Furniture and Fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,954	4,041
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,932	2,298
Manufacturing and Lab Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,536	1,388
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	470	470
Displays [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	486	488
Website [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	399	241
Office Equipment and Computers [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	141
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$561	$1,511

Balance_Sheet_Components_Addit

Balance Sheet Components - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Balance Sheet Related Disclosures [Abstract]
Depreciation and amortization expense	$382,000	$314,000
Amortization of intangible assets	$225,000	$285,000

Balance_Sheet_Components_Sched2

Balance Sheet Components - Schedule of Intangible Assets (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$10,190	$7,772
Finite-Lived Intangible Assets, Accumulated Amortization	-995	-698
Finite-Lived Intangible Assets, Net, Total	9,195	7,074
Customer Relationships [Member]
Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	3,130	3,130
Finite-Lived Intangible Assets, Accumulated Amortization	-261	-209
Finite-Lived Intangible Assets, Net, Total	2,869	2,921
Finite-Lived Intangible Asset, Useful Life	15 years	15 years
Non-Compete Agreements [Member]
Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	69	69
Finite-Lived Intangible Assets, Accumulated Amortization	-43	-35
Finite-Lived Intangible Assets, Net, Total	26	34
Finite-Lived Intangible Asset, Useful Life	9 months 18 days	2 years
Patents [Member]
Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	2,211	2,211
Finite-Lived Intangible Assets, Accumulated Amortization	-354	-293
Finite-Lived Intangible Assets, Net, Total	1,857	1,918
Finite-Lived Intangible Asset, Useful Life	7 years 9 months 18 days	7 years 9 months 18 days
Trademarks [Member]
Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	692	518
Finite-Lived Intangible Assets, Accumulated Amortization	-117	-20
Finite-Lived Intangible Assets, Net, Total	575	498
Finite-Lived Intangible Asset, Useful Life	6 years 3 months 18 days	4 years 6 months
Brand
Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,020	1,776
Finite-Lived Intangible Assets, Accumulated Amortization	-194	-118
Finite-Lived Intangible Assets, Net, Total	3,826	1,658
Finite-Lived Intangible Asset, Useful Life	9 years 2 months 12 days	15 years
Domain Name [Member]
Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	68	68
Finite-Lived Intangible Assets, Accumulated Amortization	-26	-23
Finite-Lived Intangible Assets, Net, Total	$42	$45
Finite-Lived Intangible Asset, Useful Life	5 years	5 years

Balance_Sheet_Components_Sched3

Balance Sheet Components - Schedule of Estimated Future Amortization Expense of Intangible Assets (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]
The remainder of 2015	$816
2016	1,054
2017	1,042
2018	1,031
2019	1,027
2020	983
Thereafter	3,242
Finite-Lived Intangible Assets, Net, Total	$9,195	$7,074

Other_Income_Expensenet_Detail

Other Income (Expense),net (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Other (expense) income, net:
Interest income		$223
Interest expense	-125	-39
Change in fair value of derivative liabilities		484
Gain on settlement of accounts payable		5
Loss on marketable securities		-386
Foreign currency transaction loss	-64	-30
Other	6	87
Total other (expense) income, net	($183)	$344

Debt_Additional_Information_De

Debt - Additional Information (Details) (USD $)	1 Months Ended		3 Months Ended
	Feb. 28, 2015	Sep. 30, 2014	Mar. 31, 2015	Dec. 31, 2014
	Installments
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$8,000,000
Line of Credit Facility, Expiration Date		30-Sep-17
Debt Instrument, Basis Spread on Variable Rate		2.00%
Line of Credit Facility, Interest Rate Description			prime rate plus 2%
Line of credit facility, interest rate		5.25%
Line of credit			8,000,000	8,000,000
Maximum required facility compliance covenant			3,000,000	3,000,000
Number of non-consecutive days per quarter			The Company would not have been in compliance with certain financial covenants, including requiring the balance to be at or below $3 million for a minimum of 14 non-consecutive days per quarter, under this facility as of March 31, 2015 and December 31, 2014, and received a written waiver from the bank until May 31, 2015.
Minimum required debt compliance number of non-consecutive days per quarter			14 days
Principal amount of promissory note	4,000,000
Interest rate	5.25%
Number of installments	36
Debt Instrument Maturity Date	28-Feb-18
Prepayment penalties	1.00%
Debt Issuance Costs	40,000
Treasury share used to secure promissory note	860,900
Fleet Lease Program
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$1,800,000
Fleet Lease Program | Maximum [Member]
Debt Instrument [Line Items]
Number of vehicles for lease				50

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Operating Lease Expire Term	2029
Operating Leases, Rent Expense, Net	$383,000	$297,000
Capital Lease Expire Term	2017
Capital Lease Obligations	229,000		265,000
Product Liability Insurance Deduction	10,000
Aggregate Product Liability Retained Loss	20,000,000
Lease expiration term	2018
Contractual Obligation, fair value	$50,000,000		$52,800,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Contractual Obligation, Fiscal Year Maturity Schedule (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2015	$9,178
2016	9,691
2017	9,205
2018	6,100
2019	4,167
Thereafter	11,667
Contractual Obligation, Total	50,008
Endorsement [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2015	5,280
2016	8,203
2017	9,105
2018	6,000
2019	4,167
Thereafter	11,667
Contractual Obligation, Total	44,422
Sponsorship [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2015	3,898
2016	1,488
2017	100
2018	100
Contractual Obligation, Total	$5,586

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Stockholders Equity (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Class Of Stock [Line Items]
Stock-based compensation related to issuance of restricted stock awards to employees, executives and directors	$2,523	$2,491
Stock issued in conjunction with energy drink agreement, Valuation	1,198
Stock issued in conjunction with MusclePharm apparel rights acquisition, Valuation	1,394	9,840
Total, Valuation	5,115	12,331
Stock issued in conjunction with energy drink agreement, Range of Value per Share	$7.99
Stock issued in conjunction with MusclePharm apparel rights acquisition, Range of Value per Share	$8.20	$8.20
Stock issued to employees, executives and directors, Quantity	51,805	60,422
Stock issued in conjunction with energy drink agreement, Quantity	150,000
Stock issued in conjunction with MusclePharm apparel rights acquisition, Quality	170,000	1,200,000
Total, Quantity	371,805	1,260,422
Stock issued to employees, executives and directors, Valuation	$2,523	$2,491
Minimum [Member]
Class Of Stock [Line Items]
Stock issued to employees, executives and directors, Range of Value per Share	$3.48	$3.48
Total, Range of Value per Share	$3.48	$3.48
Maximum [Member]
Class Of Stock [Line Items]
Stock issued to employees, executives and directors, Range of Value per Share	$8.60	$8.70
Total, Range of Value per Share	$8.60	$8.70

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Stockholders Equity Note [Abstract]
Number of Treasury Shares, Acquired	0	0
Treasury Stock, shares	875,621		875,621

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) (Restricted Stock, USD $)	3 Months Ended
	Mar. 31, 2015
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested Beginning Balance	2,631,987
Number of Shares, Granted	8,668
Number of Shares, Vested	-366,889
Number of Shares, Unvested Ending Balance	2,273,766
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance	$11.67
Weighted-Average Grant Date Fair Value, Granted	$8.60
Weighted-Average Grant Date Fair Value, Vested	$9.87
Weighted-Average Grant Date Fair Value, Unvested Ending Balance	$12.01

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Details) (USD $)	3 Months Ended	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Jan. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock issued in conjunction with energy drink agreement (in shares)	150,000
Total consideration related to the acquisition of the Apparel in cash	$850,000
Energy Drink Agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock issued in conjunction with energy drink agreement (in shares)		150,000
Restricted stock awards grant date fair value		1,200,000
Prepaid stock compensation amortization period		3 years
Worldwide Apparel, LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total consideration related to the acquisition of the Apparel in cash	850,000
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued	170,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	1,400,000
Finite-Lived Intangible Asset, Useful Life	7 years
Shares held in escrow release date	22-May-15
Total cost of Apparel acquisition	2,200,000
Worldwide Apparel, LLC | Escrow [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued	42,500
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock awards granted	75,000		320,000
Total unrecognized expense for unvested restricted stock awards	$18,200,000			$20,700,000
Total unrecognized expense for unvested restricted stock awards, weighted average period (in years)	3 years 1 month 6 days			2 years 7 months 6 days
Restricted Stock | Energy Drink Agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock awards vesting period		3 years

Net_Income_Loss_Per_Share_Comp

Net Income (Loss) Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Net (loss) income	($7,479)	$2,736
Weighted average shares used to compute net (loss) income per share, basic	13,333,868	10,307,350
Effect of dilutive securities		1,644,573
Weighted-average common shares used in computing net (loss) income per share, diluted	13,333,868	11,951,923
Net (loss) income per share, basic	($0.56)	$0.27
Net (loss) income per share, diluted	($0.56)	$0.23

Net_Income_Loss_Per_Share_Comp1

Net Income (Loss) Per Share - Computation of Diluted Net Loss Per Share (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,274,238	1,645,134
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	472	472
Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		263,089
Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,273,766	1,381,573

Net_Income_Loss_Per_Share_Comp2

Net Income (Loss) Per Share - Computation of Diluted Net Loss Per Share (Parenthetical) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$425	$425
Minimum [Member] | Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$4	$4
Maximum [Member] | Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$1,275	$1,275

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Provision for income taxes	$12	$32

Geographic_Information_Details

Geographic Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenue, net:
Revenue, net	$41,322	$50,209
United States [Member]
Revenue, net:
Revenue, net	31,588	33,000
International [Member]
Revenue, net:
Revenue, net	$9,734	$17,209